Helius Medical Technologies (HSDT) said Monday that it will challenge the Centers for Medicare & Medicaid Services' decision to finalize a $2,963.30 reimbursement for its portable neuromodulation stimulator mouthpiece, effective Jan. 1.
The new reimbursement determination corrects Medicare's initial decision of monthly rental payments, Helius added.
Medicare deferred its decision on the payment rate for its portable neuromodulation stimulator controller to the next payment cycle, according to the company.
Helius said it plans to continue advocating for appropriate pricing for both devices to increase patient access and drive revenue growth.
Comments